sacituzumab govitecan,Pembrolizumab,Avelumab,Zimberelimab,Domvanalimab
Gilead Sciences,Merck,Pfizer,Arcus Biosciences,Otsuka
['muc ,(-much)', 'avelumab', 'pembro', ' sg ', ' cis ', 'trophy,u-01', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', ' gem ']
#gu23 masterful presentation by results from cohort 2 of trophy-u-01: ph 2 sg in pt-ineligible pts w/ muc that progressed after cpi 32% of cr, mpfs of 5.6mo, mos of 13.5mo
awaiting results from other cohorts! 
Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow